Aclaris Therapeutics, Inc. ACRS R2KR3KPHARMA
Company Overview
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Why Investors Should Care
Revenue has grown at a 24.6% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $7.83M (-58.2% YoY); net profit $-64.92M.
- Trailing 12 Months Year-on-year growth — revenue +37.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 24.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 24.55% |
| 1 Year: | 37.20% |
Stock Price Performance
| 1 Year: | +262.94% |
| 6 Months: | +101.63% |
| 3 Months: | +41.51% |
| 1 Month: | +1.31% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)54.59 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 24.6% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ACRS Aclaris Therapeutics, Inc. R2KR3KPHARMA | 6.17 | -10.64 | $861.72M | 0.00% | -56.20% | -48.42% | 24.55% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 684.00K | 999.00K | 1.12M | 3.68M | 1.12M | 3.67M | 1.26M | 886.00K | 983.00K | 1.41M | 2.05M | 1.45M | 1.78M | 1.82M | 1.66M | 1.45M | 1.53M | 19.02M | 2.53M | 1.87M | 9.28M | 2.40M | 2.77M | - | - | 1.46M | 1.78M | 3.30M | 1.29M | 2.00M | 1.63M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.52M | 1.85M | 2.45M | 1.47M | 1.79M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | 231.00K | 245.00K | 151.00K | 2.50M | 435.00K | 160.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -61.00K | -73.00K | 850.00K | -174.00K | 208.00K | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.72M | 16.84M | 17.90M | 22.16M | 22.40M | - |
| Operating Income | -2.60M | -10.64M | - | -13.14M | -12.99M | -10.81M | - | -12.93M | -15.29M | -18.76M | - | -30.95M | -31.98M | -21.34M | - | -27.05M | -43.60M | -22.86M | -15.51M | -11.38M | -10.46M | -28.53M | -18.01M | -20.30M | -18.91M | -20.99M | -20.87M | -29.92M | -31.82M | -31.58M | -18.93M | -12.85M | - | - | -17.78M | -16.91M | -17.05M | -22.33M | -22.19M | -24.24M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -17.66M | -16.79M | -16.94M | -22.23M | -22.09M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.09M | -15.43M | -14.61M | -19.80M | -19.82M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.59M | -10.63M | -4.71M | -13.04M | -12.87M | -10.69M | -11.47M | -12.56M | -14.84M | -18.19M | -22.93M | -30.23M | -31.22M | -32.74M | -38.55M | -37.56M | -49.88M | -55.32M | -15.59M | -11.60M | -10.66M | -28.75M | -18.16M | -21.15M | -18.79M | -20.53M | -19.95M | -28.16M | -29.57M | -29.26M | -16.94M | -10.99M | - | - | -15.09M | -15.43M | -14.61M | -19.80M | -19.82M | -21.50M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.57 | -0.34 | -0.35 | -0.31 | -0.31 | -0.30 | -0.42 | -0.42 | -0.41 | -0.24 | -0.15 | - | - | -0.12 | -0.13 | -0.12 | -0.16 | -0.15 | -0.15 |
| R&D Expense | 1.79M | 9.41M | - | 9.54M | 9.84M | 7.16M | - | 7.77M | 7.96M | 10.86M | - | 13.61M | 13.98M | 15.19M | - | 19.64M | 17.52M | 16.18M | 7.68M | 6.47M | 6.24M | 7.84M | 7.90M | 13.98M | 14.31M | 18.78M | 23.66M | 22.59M | 25.27M | 23.88M | 9.85M | 8.76M | 5.96M | - | 11.58M | 11.45M | 13.03M | - | 15.66M | 18.07M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 1.68M | 6.15M | 4.23M | 6.48M | - | 29.75M | 31.25M | 18.72M | 7.83M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 11.96M | 18.08M | 15.46M | 7.28M |
| Gross Profit | - | - | - | - | 476.00K | 3.24M | - | - | - | 17.79M | 13.17M | 3.26M | 542.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 102.95M | 129.48M | 55.79M | 74.62M |
| Operating Income | -5.26M | -8.53M | -20.67M | -48.57M | -54.36M | -84.78M | -111.06M | -50.91M | - | -85.15M | -116.31M | -52.53M | -74.08M |
| EBITDA | - | - | - | - | - | - | - | - | - | -84.36M | -115.45M | -51.72M | -73.62M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | -86.91M | -88.85M | -132.06M | -64.92M |
| Tax Provision | - | - | - | - | - | - | - | - | 0 | 0 | -367.00K | 0 | - |
| Net Income | -5.24M | -8.52M | -20.56M | -48.08M | -68.52M | -132.74M | -161.35M | -51.02M | - | -86.91M | -88.48M | -132.06M | -64.92M |
| Diluted EPS | - | - | - | - | - | - | -3.90 | -1.20 | - | -1.33 | -1.27 | -1.71 | -0.53 |
| R&D Expense | 3.49M | 6.51M | 15.34M | 33.48M | 35.80M | 60.84M | 64.17M | 29.34M | 43.81M | 77.81M | 98.38M | 33.59M | 52.65M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 17.38M | 94.08M | 176.09M | 243.51M | 275.57M | 98.30M | 70.78M | - | 254.60M | 197.41M | 220.33M | 160.46M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 231.55M | 128.86M | 125.95M | 96.32M |
| Cash & Equivalents | 19.04M | 9.59M | 10.76M | 9.85M | 30.17M | 20.20M | 167.97M | 34.19M | 22.06M | - | 45.28M | 39.88M | 24.57M | 19.96M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | 623.00K | 484.00K | 298.00K | 318.00K | - |
| Total Liabilities | - | - | 1.46M | 1.55M | 6.59M | 18.25M | 60.44M | 28.39M | 33.13M | - | 56.98M | 40.23M | 64.77M | 57.38M |
| Current Liabilities | - | - | 1.45M | 1.55M | 6.22M | 12.76M | 27.34M | 22.43M | 14.87M | - | 21.94M | 30.95M | 31.60M | 28.64M |
| Long Term Debt | - | - | - | - | - | - | 29.91M | - | 10.65M | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | 693.00K | 684.00K | 426.00K | - | - |
| Total Equity | -2.19M | -9.16M | -20.75M | 92.52M | 169.49M | 225.26M | 215.12M | 69.91M | 37.65M | - | 197.62M | 157.18M | 155.55M | 103.08M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 66.69M | 70.89M | 107.85M | 120.50M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -20.37M | -34.60M | -54.66M | -100.81M | -96.44M | -38.63M | - | -67.57M | -78.33M | -20.07M | -47.11M |
| Investing Cash Flow | - | -76.95M | -61.90M | -55.69M | 9.37M | 105.68M | 6.39M | - | 12.63M | 46.22M | -69.77M | 48.37M |
| Financing Cash Flow | - | 96.41M | 116.83M | 100.39M | 128.26M | -30.32M | 18.37M | - | 72.87M | 26.71M | 74.54M | -5.86M |
| Capital Expenditure | -417.00K | -507.00K | -232.00K | -1.24M | -1.36M | -1.61M | -453.00K | - | -605.00K | -1.31M | -35.93M | -111.00K |
| Free Cash Flow | - | -20.88M | -34.84M | -55.90M | -102.17M | -98.06M | -39.09M | - | -68.17M | -79.63M | -56.01M | -47.22M |
| Net Change in Cash | - | - | - | - | - | - | - | - | 17.93M | -5.40M | -15.31M | -4.61M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 28.3% | 52.7% | - | - | - | 59.8% | 42.1% | 17.4% | 6.9% |
| Operating Margin % | - | - | - | - | -3,230.0% | -1,378.3% | -2,627.3% | -785.4% | - | -286.2% | -372.2% | -280.6% | -946.5% |
| Net Margin % | - | - | - | - | -4,071.5% | -2,158.0% | -3,817.2% | -787.0% | - | -292.1% | -283.1% | -705.5% | -829.6% |
| ROE % | 57.1% | 41.0% | -22.2% | -28.4% | -30.4% | -61.7% | -230.8% | -135.5% | - | -44.0% | -56.3% | -84.9% | -63.0% |
| ROCE % | - | -53.6% | -22.3% | -28.6% | -23.6% | -34.2% | -146.4% | -91.1% | - | -36.6% | -69.9% | -27.8% | -56.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 9.10% | 12.72M | $76.47M |
| 2 | BML Capital Management, LLC | 8.56% | 11.97M | $71.97M |
| 3 | Blackrock Inc. | 7.18% | 10.04M | $60.32M |
| 4 | Deep Track Capital, Lp | 6.68% | 9.35M | $56.16M |
| 5 | Vivo Capital, LLC | 4.79% | 6.69M | $40.23M |
| 6 | Vanguard Capital Management LLC | 4.16% | 5.82M | $34.97M |
| 7 | Frazier Life Sciences Management, L.P. | 3.52% | 4.93M | $29.60M |
| 8 | Rock Springs Capital Management, LP | 3.10% | 4.33M | $26.03M |
| 9 | Adage Capital Partners GP L.L.C. | 2.91% | 4.07M | $24.47M |
| 10 | Decheng Capital LLC | 2.89% | 4.04M | $24.29M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ACRS
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.…
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of +6.25% and +17.19%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?
Aclaris (ACRS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.…
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052
Aclaris Therapeutics (NASDAQ:ACRS) executives outlined a busy clinical calendar for the biotechnology company during a fireside chat at the Jefferies 2026 Global Healthcare Conference, highlighting upcoming readouts across its immunology pi…
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
WAYNE, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thur…
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
WAYNE, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thur…
ACRS — Frequently Asked Questions
What is the current share price of Aclaris Therapeutics, Inc. (ACRS)?
As of 2026-09-07 16:24 PDT, Aclaris Therapeutics, Inc. (ACRS) trades at $6.17 on NasdaqGS. Its 52-week range is $1.69 to $6.54.
What is the market capitalisation of ACRS?
Aclaris Therapeutics, Inc. (ACRS) has a market capitalisation of $861.72M on NasdaqGS.
What is the P/E ratio of ACRS?
ACRS trades at a trailing price-to-earnings (P/E) ratio of -10.64. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 6.91.
What is the return on equity (ROE) of ACRS?
ACRS has a return on equity (ROE) of -48.42%. Its return on capital employed (ROCE) is -56.20%.
Is ACRS a good stock to buy?
This page provides a data-driven analysis of Aclaris Therapeutics, Inc. (ACRS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.